Extended survival observed in adoptive activated T lymphocyte immunotherapy for advanced lung cancer: results of a multicenter historical cohort study
| العنوان: | Extended survival observed in adoptive activated T lymphocyte immunotherapy for advanced lung cancer: results of a multicenter historical cohort study |
|---|---|
| المؤلفون: | Kenzo Soejima, Hitoshi Tokuda, Tetsuo Yamaguchi, Shigenori Goto, Takashi Kamigaki, Kouji Yoshimori, Yasuhiro Setoguchi, Yoshimasa Umezato, Katsunada Fujimoto, Toru Kaneko, Akira Mizoo, Shoji Kudoh, Kazuro Iwai |
| المصدر: | Cancer Immunology, Immunotherapy |
| بيانات النشر: | Springer-Verlag, 2012. |
| سنة النشر: | 2012 |
| مصطلحات موضوعية: | Interleukin 2, Oncology, Male, medicine.medical_specialty, Cancer Research, Lung Neoplasms, CD3 Complex, medicine.medical_treatment, T-Lymphocytes, Immunology, Adenocarcinoma of Lung, Adenocarcinoma, Lymphocyte Activation, Immunotherapy, Adoptive, Severity of Illness Index, Cohort Studies, Adoptive immunotherapy, Internal medicine, Carcinoma, medicine, T lymphocyte, Immunology and Allergy, Humans, Overall survival, Lung cancer, Cells, Cultured, Advanced lung cancer, Aged, Performance status, business.industry, Cancer, Immunotherapy, Middle Aged, medicine.disease, Antibodies, Neutralizing, Combined Modality Therapy, Treatment Outcome, Carcinoma, Squamous Cell, Additive effect, Interleukin-2, Original Article, Female, business, medicine.drug |
| الوصف: | Purpose To clarify the long-term effect of immunotherapy, the effect of adoptive activated T lymphocyte immunotherapy on advanced lung cancer was evaluated in terms of survival time. In addition, the performance status of cancer patients under immunotherapy was examined. Experimental design Over 5 × 109 alpha–beta T lymphocytes cultured ex vivo with an immobilized anti-CD3 antibody and interleukin-2 were injected intravenously into patients, once every 2 weeks for 3 months or longer. Follow-up of these patients was carried out using clinical records and by telephone interview questionnaire. Patients undergoing immunotherapy in immunotherapy clinics and those undergoing other anticancer therapies without immunotherapy in seven hospitals in Tokyo were enrolled in this study. Data were analyzed by a third-party statistician. Performance status was studied on another series of various cancer patients who underwent immunotherapy. Results The overall median survival time of the patients with the best supportive care, which was obtained using Kaplan–Meier’s model, was 5.6 months, and those with immunotherapy alone, chemotherapy alone, and immuno-chemotherapy were 12.5, 15.7, and 20.8 months, respectively. Using Cox’ proportional hazard model, we examined the possible factors on survival time by univariate analysis. Then, the patients were stratified by gender and histological type for multivariate analysis. Significantly low hazard ratios were observed for immunotherapy and radiotherapy in males with squamous cancer; for chemotherapy and radiotherapy in male with adenocarcinoma; and for immunotherapy in females with adenocarcinoma. Addition of immunotherapy to chemotherapy resulted in a statistically significant decrease in hazard ratio in females with adenocarcinoma. Studies on the performance status (PS), determined according to the European Cooperative Oncology Group criteria, revealed a continuous high level of PS under immunotherapy until around 2 months before death, in contrast to the gradual increase of tumor marker level. Conclusions The effectiveness of immunotherapy on advanced lung cancer is limited but may extend life span under certain conditions. Immunotherapy itself provided no clinical benefit by itself as compared with chemotherapy, but a significant additive effect of immunotherapy on chemotherapy was observed in females with adenocarcinoma. Moreover, immunotherapy can maintain good quality of life of the patients until near the time of death. |
| اللغة: | English |
| تدمد: | 1432-0851 0340-7004 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2158d75345868b0b5929f16575c9649c http://europepmc.org/articles/PMC3448049 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....2158d75345868b0b5929f16575c9649c |
| قاعدة البيانات: | OpenAIRE |
Find this article in full text from Springer Verlag. | تدمد: | 14320851 03407004 |
|---|